← Back to Clinical Trials
Recruiting NCT04344769

Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Trial Parameters

Condition Autosomal Dominant Polycystic Kidney Disease
Sponsor Mayo Clinic
Study Type OBSERVATIONAL
Phase N/A
Enrollment 40
Sex ALL
Min Age 18 Years
Max Age 30 Years
Start Date 2019-10-04
Completion 2026-12

Brief Summary

The purpose of this study is to characterize oxidative stress and the Nrf2 antioxidant response in early stages of Autosomal Dominant Polycystic Kidney Disease (ADPKD), while identifying candidate biomarkers.

Eligibility Criteria

Inclusion Criteria (ADPKD Subjects): * ADPKD (based on Ravine et al. criteria) * Class 1 B-E according to our imaging classification * Male and female subjects 18 - 30 years of age, inclusive * Estimated GFR\> 60 mL/min/m2 (CKD-EPI equation) * Ability to provide written, informed consent. Exclusion Criteria (ADPKD Subjects): * Class 2 according to our imaging classification * Concomitant systemic disease in the kidney (e.g. lupus, hepatitis B or C, amyloidosis) * Diabetes mellitus (fasting glucose \> 126 mg/dL or treatment with insulin or oral hypoglycemics). * Predicted urine protein excretion in urinalysis \>1 g/24 hrs * Abnormal urinalysis suggestive of concomitant glomerular disease. * Subjects having contraindications to, or interference with MRI assessments. \[For example: ferromagnetic metal prostheses, aneurysm clips, severe claustrophobia, large abdominal/back tattoos, etc\]. * Female subjects that are pregnant Inclusion Criteria (Healthy Subjects): * Male and female subjects

Related Trials